To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Phase 3 Not yet recruiting 250 enrolled Eidos Therapeutics, a BridgeBio company

NaSingle-groupOpen-labelTreatment

Summary

The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).

Timeline

Start: 2025-11
Primary completion: 2037-11
Completion: 2037-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acoramidis	Unknown	712 mg	Oral

To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

Summary

Timeline

Drugs

Indications